---
title: "Alkermes plc Director Shane Cooke Sells Shares"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/274583465.md"
description: "Shane Cooke, a Director at Alkermes plc, sold 61,200 ordinary shares on February 2, 2026, under a Rule 10b5-1 trading plan. The sales included 29,087 shares at an average price of $34.34 and 32,113 shares at $34.78, totaling $2,115,672. After the sales, Cooke retains 103,744 shares in the company."
datetime: "2026-02-03T01:50:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274583465.md)
  - [en](https://longbridge.com/en/news/274583465.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274583465.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/274583465.md) | [繁體中文](https://longbridge.com/zh-HK/news/274583465.md)


# Alkermes plc Director Shane Cooke Sells Shares

Shane Cooke, a Director at Alkermes plc, sold a total of 61,200 ordinary shares on February 2, 2026, under a Rule 10b5-1 trading plan. The transactions occurred in two parts, with 29,087 shares sold at a weighted average price of $34.3382 and 32,113 shares at $34.7796, totaling $2,115,672. Following these transactions, Cooke directly owns 103,744 ordinary shares of Alkermes plc.

Reporter Name

Cooke Shane

Relationship

Director

Type

Sell

Amount

$2,115,672

SEC Filing

Form 4

SEC Filing: Alkermes plc. \[ ALKS \] - Form 4 - Feb. 02, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### 相关股票

- [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-CN/quote/BIB.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-CN/quote/PBE.US.md)
- [VG Health (VHT.US)](https://longbridge.com/zh-CN/quote/VHT.US.md)
- [Health Care Select Sector SPDR (XLV.US)](https://longbridge.com/zh-CN/quote/XLV.US.md)
- [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-CN/quote/ARKG.US.md)
- [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-CN/quote/XBI.US.md)
- [Alkermes (ALKS.US)](https://longbridge.com/zh-CN/quote/ALKS.US.md)
- [iShares US Pharma (IHE.US)](https://longbridge.com/zh-CN/quote/IHE.US.md)
- [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-CN/quote/SBIO.US.md)
- [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-CN/quote/FBT.US.md)
- [Direxion S&P Biotech Bear 3X (LABD.US)](https://longbridge.com/zh-CN/quote/LABD.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-CN/quote/BBH.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-CN/quote/IBB.US.md)

## 相关资讯与研究

- [Alkem Laboratories Gets Board Nod to Boost Investment in New Factory](https://longbridge.com/zh-CN/news/281495465.md)
- [TD Cowen Sticks to Their Buy Rating for Alkermes (ALKS)](https://longbridge.com/zh-CN/news/281419637.md)
- [Iterum Therapeutics Received Notice of Delisting](https://longbridge.com/zh-CN/news/281174211.md)
- [Assenagon Asset Management S.A. Decreases Stock Position in BridgeBio Pharma, Inc. $BBIO](https://longbridge.com/zh-CN/news/281143495.md)
- [Nuvalent CFO Alexandra Balcom sells $1.2 million Class A common shares](https://longbridge.com/zh-CN/news/281660994.md)